Literature DB >> 24793151

Pulmonary embolism in a young male with tuberculosis and factor V Leiden.

Marcin Skowroński1, Waldemar Elikowski, Anna Halicka, Aleksander Barinow-Wojewódzki.   

Abstract

There is no doubt that venous thromboembolism (VTE) is a complex and multicausal disease. Tuberculosis (TB) itself is found to have thrombogenic potential. There is an association between tuberculosis and VTE. We present a case of a 31-year-old male diagnosed with TB after a 2-month delay. He was treated with an anticoagulant for pulmonary embolism (PE) complicated by pulmonary infarction, and with antibiotics for presumed bacterial pneumonia. The patient did not improve despite in-hospital treatment. Finally, TB was diagnosed with positive sputum smear for acid fast bacilli and subsequent culture of Mycobacterium tuberculosis. Antituberculous therapy was uneventful and the patient was discharged home. Thrombophilia screening revealed a heterozygous factor V Leiden mutation. This case report emphasises that although there is a steady decline in active cases of TB, it should be still placed high on the list as a differential diagnosis in non-resolving lung infection or pulmonary infarction. This is especially relevant in cases with typical radiological findings located in the upper lobes. On the other hand, definitive diagnosis may be challenging in a case of concurrent TB, bacterial pneumonia and pulmonary infarction. Thromboembolic events may develop in TB patients without any clinical VTE risk factors. Therefore, thromboprophylaxis should be cautiously considered in this group of patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24793151     DOI: 10.5603/PiAP.2014.0031

Source DB:  PubMed          Journal:  Pneumonol Alergol Pol        ISSN: 0867-7077


  1 in total

Review 1.  Severe pulmonary tuberculosis complicated with insidious pulmonary thromboembolism: a case report and literature review.

Authors:  Lili Huang; Chunyang Yin; Xiaoyan Gu; Xiaojun Tang; Xia Zhang; Chunmei Hu; Wei Chen
Journal:  J Thromb Thrombolysis       Date:  2020-05       Impact factor: 2.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.